Clinical utility of ramucirumab in advanced gastric cancer

por Chan, Matthew MK, Sjoquist, Katrin M, Zalcberg, John R
Publicado 2015

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

por Sjoquist, Katrin M., Lord, Sarah J., Friedlander, Michael L., John Simes, Robert, Marschner, Ian C., Lee, Chee Khoon
Publicado 2018

Challenges of international oncology trial collaboration—a call to action

por Tang, Monica, Joensuu, Heikki, Simes, Robert J., Price, Timothy J., Yip, Sonia, Hague, Wendy, Sjoquist, Katrin M., Zalcberg, John
Publicado 2019

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis

por Chan, David L., Sjoquist, Katrin M., Goldstein, David, Price, Timothy J., Martin, Andrew J., Bang, Yung-Jue, Kang, Yoon-Koo, Pavlakis, Nick
Publicado 2017

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

por Sjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R., Simes, R. John
Publicado 2022

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

por Kok, Peey-Sei, Beale, Philip, O'Connell, Rachel L., Grant, Peter, Bonaventura, Tony, Scurry, James, Antill, Yoland, Goh, Jeffrey, Sjoquist, Katrin, DeFazio, Anna, Mapagu, Cristina, Amant, Frederic, Friedlander, Michael
Publicado 2019

Accuracy of oncologists’ estimates of expected survival time in advanced cancer

por Nahm, Sharon H, Martin, Andrew J, Clayton, Josephine M, Grimison, Peter, Moth, Erin B, Pavlakis, Nick, Sjoquist, Katrin, Smith-Uffen, Megan E S, Tognela, Annette, Vasista, Anuradha, Stockler, Martin R, Kiely, Belinda E
Publicado 2023

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pa...

por Oar, Andrew, Lee, Mark, Le, Hien, Wilson, Kate, Aiken, Chris, Chantrill, Lorraine, Simes, John, Nguyen, Nam, Barbour, Andrew, Samra, Jaswinder, Sjoquist, Katrin M., Moore, Alisha, Espinoza, David, Gebski, Val, Yip, Sonia, Chu, Julie, Kneebone, Andrew, Goldstein, David
Publicado 2021

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

por Tebbutt, Niall C, Price, Timothy J, Ferraro, Danielle A, Wong, Nicole, Veillard, Anne-Sophie, Hall, Merryn, Sjoquist, Katrin M, Pavlakis, Nick, Strickland, Andrew, Varma, Suresh C, Cooray, Prasad, Young, Rosemary, Underhill, Craig, Shannon, Jennifer A, Ganju, Vinod, Gebski, Val
Publicado 2016

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a...

por Siu, Ho Wai Derrick, Tebbutt, Niall, Chantrill, Lorraine, Karapetis, Chris, Steer, Christopher, Wilson, Kate, Espinoza, David, Bailey, Lisa, Yip, Sonia, Cuff, Jeff, Pavlakis, Nick, Thavaneswaran, Subotheni, Briscoe, Karen, Srivastav, Ratnesh, Shannon, Jennifer, Segelov, Eva, Tie, Jeannie, Caird, Susan, Francesconi, Alessandra, Price, Timothy, Wuttke, Melanie, Ladwa, Rahul, Sjoquist, Katrin, Burge, Matthew
Publicado 2021

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by...

por Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John, Goldstein, David
Publicado 2023